Exposure–efficacy and exposure–safety analyses of ropeginterferon alfa‐2b treatment in patients with polycythaemia vera
British Journal of Clinical Pharmacology · 2024-06 · 90 (6) · 1493-1502
DOI: 10.1111/bcp.16043 ↗At a glance
Klinische Studie (Phase II) in British Journal of Clinical Pharmacology, published online on 2024-03-19. Written by Albert Qin and 11 co-authors. Institution: Medical Research & Clinical Operations, PharmaEssentia Corporation, Taipei, Taiwan, ROC. Major MEDLINE topics: Recombinant Proteins, Interferon-alpha, Polyethylene Glycols, Interferon alpha-2. Cited 22 times so far (Crossref); 40 references. Funded by: PharmaEssentia Corporation.
Abstract (original language)
Aims
To investigate the exposure–response (E‐R) relationship, including exposure–efficacy and exposure–safety, of ropeginterferon alfa‐2b treatment in patients with polycythaemia vera (PV).
Methods
Based on the results of the phase II trial A20‐202 regarding ropeginterferon alfa‐2b in patients with PV, E‐R analyses were performed to evaluate the efficacy and safety of the given dosing regimen. The E‐R analyses were based on logistic and linear regression and the relationship between exposure to ropeginterferon alfa‐2b and key efficacy and safety variables. The key efficacy variables included complete haematologic response (CHR) and reduction of the driver mutation JAK2 V617F. The safety variable was treatment‐related adverse events (TRAEs).
Results
A clear relationship between the exposure to ropeginterferon alfa‐2b and CHR was observed, with an increase in drug exposure resulting in an increased probability of achieving CHR. Similar CHR probabilities were observed in the third and fourth quantiles of the average concentration at Week 24. The results from the exposure– JAK2 V617F model indicated that the JAK2 V617F allele burden decreased with increasing exposure to ropeginterferon alfa‐2b and baseline body surface area. Exposure–safety analysis revealed a risk of AEs associated with transaminase abnormalities, which were not associated with clinical significance.
Conclusions
Our analyses have shown that patients with PV treated with ropeginterferon alfa‐2b had an increased probability of achieving CHR and a molecular response with acceptable safety risks at the 250–350–500 μg titration dosing regimen. This study has provided the relevant data for the application of a biologics licence of ropeginterferon alfa‐2b for PV treatment in China.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Medical Research & Clinical Operations, PharmaEssentia Corporation, Taipei, Taiwan, ROC.
- PharmaEssentia Biotech (Beijing) Limited, Beijing, China.
- Pharmaron Clinical Services Co., Ltd, Chengdu, China.
ORCID profiles: Albert Qin
Funding
- PharmaEssentia Corporation
Cite
APA
Qin, A., Wu, D., Li, Y., Zhang, J., Wang, W., Shen, W., Liao, J., Lin, S., Chang, C., Chen, H., Cui, J., & Su, X. (2024). Exposure–efficacy and exposure–safety analyses of ropeginterferon alfa‐2b treatment in patients with polycythaemia vera. British Journal of Clinical Pharmacology, 90(6), 1493-1502. https://doi.org/10.1111/bcp.16043
Vancouver
Qin A, Wu D, Li Y, Zhang J, Wang W, Shen W, et al. Exposure–efficacy and exposure–safety analyses of ropeginterferon alfa‐2b treatment in patients with polycythaemia vera. British Journal of Clinical Pharmacology. 2024;90(6):1493-1502. doi:10.1111/bcp.16043
BibTeX
@article{Qin2024,
author = {Qin, Albert and Wu, Daoxiang and Li, Yaning and Zhang, Jingjing and Wang, Wei and Shen, Weihong and Liao, Jason and Lin, Sheena and Chang, Cynthia and Chen, Haoqi and Cui, Jie and Su, Xia},
title = {Exposure–efficacy and exposure–safety analyses of ropeginterferon alfa‐2b treatment in patients with polycythaemia vera},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
volume = {90},
number = {6},
pages = {1493--1502},
doi = {10.1111/bcp.16043}
}
EUVIMED